



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
14.09.2022 Bulletin 2022/37

(45) Date of publication and mention
of the grant of the patent:
10.08.2022 Bulletin 2022/32

(21) Application number: **17853838.5**

(22) Date of filing: **20.09.2017**

(51) International Patent Classification (IPC):
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 29/00 ^(2006.01) **A61P 35/00** ^(2006.01)
A61P 37/06 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61P 1/04; A61P 3/10; A61P 9/00; A61P 9/10;
A61P 11/00; A61P 11/06; A61P 13/12;
A61P 15/00; A61P 17/00; A61P 17/04;
A61P 17/06; A61P 19/02; A61P 21/00;
A61P 21/04; A61P 25/28; (Cont.)

(86) International application number:
PCT/US2017/052592

(87) International publication number:
WO 2018/057669 (29.03.2018 Gazette 2018/13)

(54) **ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE**
ANTIKÖRPER GEGEN SIGNALREGULATORISCHES PROTEIN ALPHA UND VERFAHREN ZUR
VERWENDUNG
ANTICORPS CONTRE LA PROTÉINE RÉGULATRICE DE SIGNAL ALPHA ET PROCÉDÉS
D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: **21.09.2016 US 201662397752 P**
05.06.2017 US 201762515480 P

(43) Date of publication of application:
31.07.2019 Bulletin 2019/31

(60) Divisional application:
22179377.1

(73) Proprietor: **ALX Oncology Inc.**
South San Francisco, CA 94080 (US)

(72) Inventors:
• **PONS, Jaume**
Burlingame, CA 94010 (US)
• **SIM, Bang Janet**
Burlingame, CA 94010 (US)
• **WAN, Hong**
Burlingame, CA 94010 (US)
• **KUO, Tracy Chia-Chien**
Burlingame, CA 94010 (US)
• **KAUDER, Steven Elliot**
Burlingame, CA 94010 (US)
• **HARRIMAN, William Don**
Emeryville, CA 94608-2059 (US)
• **IZQUIERDO, Shelley**
Emeryville, CA 94608-2059 (US)

(74) Representative: **J A Kemp LLP**
80 Turnmill Street
London EC1M 5QU (GB)

(56) References cited:
WO-A1-2013/056352 WO-A1-2016/063233
WO-A1-2016/063233 WO-A2-2015/138600

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

US-A1- 2003 054 415 US-A1- 2003 054 415

- SEIFFERT M ET AL: "HUMAN SIGNAL-REGULATORY PROTEIN IS EXPRESSED ON NORMAL, BUT NOT ON SUBSETS OF LEUKEMIC MYELOID CELLS AND MEDIATES CELLULAR ADHESION INVOLVING ITS COUNTERRECEPTOR CD47", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 94, no. 11, 1 December 1999 (1999-12-01), pages 3633-3643, XP000973562, ISSN: 0006-4971
- M. SEIFFERT: "Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38-hematopoietic cells", BLOOD, vol. 97, no. 9, 1 May 2001 (2001-05-01), pages 2741-2749, XP055056672, ISSN: 0006-4971, DOI: 10.1182/blood.V97.9.2741
- W. Y. LEE ET AL: "Novel Structural Determinants on SIRP that Mediate Binding to CD47", THE JOURNAL OF IMMUNOLOGY, vol. 179, no. 11, 19 November 2007 (2007-11-19), pages 7741-7750, XP055497847, ISSN: 0022-1767, DOI: 10.4049/jimmunol.179.11.7741
- X. W. ZHAO ET AL: "CD47-signal regulatory protein-? (SIRP?) interactions form a barrier for antibody-mediated tumor cell destruction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 45, 8 November 2011 (2011-11-08), pages 18342-18347, XP055055636, ISSN: 0027-8424, DOI: 10.1073/pnas.1106550108
- JOANNE E NETTLESHIP ET AL: "Crystal structure of signal regulatory protein gamma (SIRP[gamma]) in complex with an antibody Fab frag", BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 13, no. 1, 4 July 2013 (2013-07-04), page 13, XP021156553, ISSN: 1472-6807, DOI: 10.1186/1472-6807-13-13
- SEIFFERT, M. ET AL.: 'Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD 47' BLOOD vol. 94, no. 11, 1999, pages 3633 - 3643, XP000973562
- SEIFFERT, M. ET AL.: 'Signal-regulatory protein a (SIRPa) but not SIRPb is involved in T- cell activation, binds to CD 47 with high affinity, and is expressed on immature CD 34+ CD 38- hematopoietic cells' BLOOD vol. 97, no. 9, pages 2741 - 2749, XP055056672
- LEE, W. ET AL.: 'Novel Structural Determinants on SIRPa that Mediate Binding to CD 47' THE JOURNAL OF IMMUNOLOGY vol. 179, 2007, pages 7741 - 7750, XP055497847
- ZHAO, X. ET AL.: 'CD 47-signal regulatory protein-a (SIRPa) interactions form a barrier for antibody-mediated tumor cell destruction' PNAS USA vol. 108, no. 45, 2011, pages 18342 - 18347, XP055055636
- NETTLESHIP, J. ET AL.: 'Crystal structure of signal regulatory protein gamma (SIRPg) in complex with an antibody Fab fragment' BMC STRUCTURAL BIOLOGY vol. 13, 2013, pages 1 - 8, XP021156553

(52) Cooperative Patent Classification (CPC): (Cont.)
 A61P 29/00; A61P 31/04; A61P 35/00;
 A61P 37/00; A61P 37/06; C07K 16/2803;
 A61K 2039/505; A61K 2039/507; C07K 16/2827;
 C07K 2317/23; C07K 2317/24; C07K 2317/30;
 C07K 2317/34; C07K 2317/622; C07K 2317/76;
 C07K 2317/92